Zelira Therapeutics ZLDAF Stock
Zelira Therapeutics Price Chart
Zelira Therapeutics ZLDAF Financial and Trading Overview
Zelira Therapeutics stock price | 0.3 USD |
Previous Close | 1.25 USD |
Open | 1.15 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 1.25 - 1.25 USD |
52 Week Range | 0.55 - 2.53 USD |
Volume | 1K USD |
Avg. Volume | 177 USD |
Market Cap | 14.18M USD |
Beta (5Y Monthly) | 0.595402 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.26 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
ZLDAF Valuation Measures
Enterprise Value | 12.56M USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 15.939335 |
Price/Book (mrq) | 0.37235627 |
Enterprise Value/Revenue | 14.118 |
Enterprise Value/EBITDA | -1.15 |
Trading Information
Zelira Therapeutics Stock Price History
Beta (5Y Monthly) | 0.595402 |
52-Week Change | 82.72% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.53 USD |
52 Week Low | 0.55 USD |
50-Day Moving Average | 0.77 USD |
200-Day Moving Average | 0.77 USD |
ZLDAF Share Statistics
Avg. Volume (3 month) | 177 USD |
Avg. Daily Volume (10-Days) | 580 USD |
Shares Outstanding | 11.35M |
Float | 6.63M |
Short Ratio | N/A |
% Held by Insiders | 37.36% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:175 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -1269.16% |
Gross Margin | 23.72% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -18.36% |
Return on Equity (ttm) | -28.71% |
Income Statement
Revenue (ttm) | 889.87K USD |
Revenue Per Share (ttm) | 0.1 USD |
Quarterly Revenue Growth (yoy) | -89.40% |
Gross Profit (ttm) | 601.57K USD |
EBITDA | -10928264 USD |
Net Income Avi to Common (ttm) | -9956218 USD |
Diluted EPS (ttm) | -0.73 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 133.79K USD |
Total Cash Per Share (mrq) | 0.01 USD |
Total Debt (mrq) | 494.19K USD |
Total Debt/Equity (mrq) | 1.53 USD |
Current Ratio (mrq) | 1.161 |
Book Value Per Share (mrq) | 3.357 |
Cash Flow Statement
Operating Cash Flow (ttm) | -8406495 USD |
Levered Free Cash Flow (ttm) | -4236170 USD |
Profile of Zelira Therapeutics
Country | United States |
State | WA |
City | Perth |
Address | 101 St George's Terrace |
ZIP | 6000 |
Phone | 61 8 6558 0886 |
Website | https://www.zeliratx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
Q&A For Zelira Therapeutics Stock
What is a current ZLDAF stock price?
Zelira Therapeutics ZLDAF stock price today per share is 0.3 USD.
How to purchase Zelira Therapeutics stock?
You can buy ZLDAF shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Zelira Therapeutics?
The stock symbol or ticker of Zelira Therapeutics is ZLDAF.
Which industry does the Zelira Therapeutics company belong to?
The Zelira Therapeutics industry is Biotechnology.
How many shares does Zelira Therapeutics have in circulation?
The max supply of Zelira Therapeutics shares is 12.04M.
What is Zelira Therapeutics Price to Earnings Ratio (PE Ratio)?
Zelira Therapeutics PE Ratio is now.
What was Zelira Therapeutics earnings per share over the trailing 12 months (TTM)?
Zelira Therapeutics EPS is -0.26 USD over the trailing 12 months.
Which sector does the Zelira Therapeutics company belong to?
The Zelira Therapeutics sector is Healthcare.